1. Post-transcriptional gene regulation by the RNA binding protein IGF2BP3 is critical for MLL-AF4 mediated leukemogenesis
- Author
-
Oscar Silva, Tasha Lin, Dinesh S. Rao, J. King, Jaspal Bassi, Jeremy R. Sanford, Tiffany M. Tran, Amit Kumar Jaiswal, May Paing, Jayanth Kumar Palanichamy, Jolene M. Draper, Neha Nibber, Julia Philipp, and Sol Katzman
- Subjects
Regulation of gene expression ,RNA-binding protein ,Biology ,medicine.disease ,Fusion protein ,Leukemogenic ,Transcriptome ,Leukemia ,Haematopoiesis ,hemic and lymphatic diseases ,medicine ,Cancer research ,Progenitor cell ,neoplasms - Abstract
Despite recent advances in therapeutic approaches, patients with MLL-rearranged leukemia still have poor outcomes and a high risk of relapse. Here, we found that MLL-AF4, the most common MLL fusion protein in patients, transcriptionally induces IGF2BP3 and that IGF2BP3 strongly amplifies MLL-Af4 mediated leukemogenesis. Deletion of Igf2bp3 significantly increases the survival of mice with MLL-Af4 driven leukemia and greatly attenuates disease, with a minimal impact on baseline hematopoiesis. At the cellular level, MLL-Af4 leukemia-initiating cells require Igf2bp3 for their function in leukemogenesis. eCLIP and transcriptome analysis of MLL-Af4 transformed stem and progenitor cells and MLL-Af4 bulk leukemia cells reveals a complex IGF2BP3-regulated post-transcriptional operon governing leukemia cell survival and proliferation. Regulated mRNA targets include important leukemogenic genes such as those in the Hoxa locus and numerous genes within the Ras signaling pathway. Together, our findings show that IGF2BP3 is an essential positive regulator of MLL-AF4 mediated leukemogenesis and represents an attractive therapeutic target in this disease.
- Published
- 2020